Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Lab-on-a-chip could speed up treatment of drug-resistant pneumonia

15.11.2006
The emergency treatment of drug-resistant infections with targeted antibiotics is often delayed by the need to identify bacterial strains by growing them in culture first.

At this week's AVS 53rd International Symposium & Exhibition in San Francisco, Michael Lochhead, a bioengineer at the Denver biotechnology company Accelr8, described a new lab-on-a-chip that can identify single bacterial cells for the most common cases of drug-resistant pneumonia, cutting down the wait from days to hours. The technology could also help in the development of new drugs.

The constant bombardment by antibiotics and disinfectants has bred strains of super-bugs that only respond to very specific drugs. These super-bugs often lurk in hospitals, where patients with weakened immune systems can pick up obstinate, life-threatening infections such as pneumonia. "When you get pneumonia in the hospital, you're much more likely to get a resistant strain," Lochhead said. "It's an emerging public-health disaster."

The most acute cases are admitted into intensive care units, where doctors have just days, if not hours, to save the patients' lives, Lochhead said. But reliably identifying the bacterial strain that's causing the infection traditionally requires growing the bugs in culture first, a procedure that can take two to three days. Meanwhile, doctors often have no other option than to start stopgap treatments with broad-spectrum antibiotics.

... more about:
»Lochhead »antibiotics »bacterial »organism »pneumonia

The Accelr8 technology is a "microfluidic" lab-on-a-chip designed to manipulate and analyze bacteria without growing them first. Samples are first washed out of the patient's lungs with saline solution in a procedure called bronchoalveolar lavage. The organisms are then separated, suspended in a specially designed fluid, and pumped into the chip.

Inside the chip, the bacteria flow into several different compartments -- eight in the current version of the chip -- and are made to stick to a bacteria-friendly surface using an electric current. Antibodies then flow in. The antibodies bind specifically to certain strains of bacteria, and mark them with fluorescent dyes of different colors. The dyes color-code cells from known strains. A microscope monitors the viable cells -- those that are still reproducing -- and the rate at which they duplicate helps to identify their species.

In the next step, different antibiotics are pumped into the chambers. If the cells in a chamber stop reproducing, that indicates that a certain drug is likely to be effective at fighting the infection. The death of the bugs is confirmed by checking with a special dye.

Once the bacteria-carrying fluid is injected into the chip, the entire procedure is automatic-- including the counting of fluorescent-marked cells, which is done by a computer -- and takes less than eight hours.

One of the most difficult steps was to design a surface that would be hospitable to the bacteria but that would at the same time keep the antibodies and antibiotics from sticking to it, Lochhead said. While Accelr8 is working on finding a "universal" material that will allow virtually all pathogenic bacteria to stick to it, the company has so far focused on nine bacterial species that cause most of the cases of drug-resistant pneumonia, including Staphylococcus aureus (staph), Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli (E. coli). "If we can characterize the nine panel organisms, we'll cover 80 to 90 percent of hospital-acquired pneumonia cases," Lochhead said.

The company also hopes to apply the technology not just to identifying known strains but also to testing the efficacy of new drugs, or of existing drugs on unknown strains. "Even if you don't know the identity of an organism, if you know which drug works, it's still useful," Lochhead says.

Accelr8, a former software company that refashioned itself into a biotechnology company, plans to place development instruments in collaborating clinical laboratories within a year.

Paper: "Microfluidic Devices That Capture Bacteria for Growth and Kill Analysis," Tuesday, November 14, 2006, 9:40am, Room 2001, AVS 53rd International Symposium & Exhibition, San Francisco, CA, abstract at http://www.avssymposium.org/paper.asp?abstractID=199

Davide Castelvecchi | EurekAlert!
Further information:
http://www.aip.org

Further reports about: Lochhead antibiotics bacterial organism pneumonia

More articles from Life Sciences:

nachricht What the world's tiniest 'monster truck' reveals
23.08.2017 | American Chemical Society

nachricht Treating arthritis with algae
23.08.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

What the world's tiniest 'monster truck' reveals

23.08.2017 | Life Sciences

Treating arthritis with algae

23.08.2017 | Life Sciences

Witnessing turbulent motion in the atmosphere of a distant star

23.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>